A Food and Drug Administration advisory committee voted 13-0 to endorse the safety and effectiveness of Merck and Co.'s GARDASIL(r) (Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine) which is so far tested in more than 27,000 females and males at Whitehouse Station, N.J. hub of Merck Inc. According to Merck, the vaccine could be used in females age 9 to 26, but would work best when given to girls before they begin having sex. Final decision on vaccine approval and vaccination strategy is expected in June 2006.
[Link]
Track relevant updates at:
--
